Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02122861 | Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | PHASE1 | COMPLETED | 47 | — | — | May 30, 2014 | Dec 15, 2018 | Mar 6, 2019 | 7 | United States |
Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\].
| Arm | Type | Description |
|---|---|---|
| ID-LV305 | EXPERIMENTAL | Dose escalation and expansion cohort including treatment of melanoma |
| Name | Type | Description |
|---|---|---|
| ID-LV305 | BIOLOGICAL | pembrolizumab |
Inclusion Criteria: * Locally advanced, relapsed, and/or metastatic cancer with low or minimal tumor burden which may or may not be measurable; no tumor size criteria are used. * Tumor histology consistent with melanoma tumor specimen positive for NY-ESO-1 expression by IHC and/or RT-PCR. * b. In P...